Hypoxic bradycardia: an enigma in coronavirus disease 2019





Bradycardia, COVID-19, Cytokine storm, Cardiovascular


Coronavirus disease 2019 varies from asymptomatic to severe acute respiratory syndrome with multiple organ involvement, primarily involving the microvasculature and heart. Acute myocardial injury is the most frequently observed and reported cardiac complication with acute coronary events, acute left ventricular systolic dysfunction, and cardiac arrhythmias, but sinus bradycardia reported only in a few cases. The development of sinus bradycardia can be crucial warning sign of onset of severe cytokine storm. The primary determinant of severity of COVID-19 is aging and co-morbidities such as diabetes and hyperlipidemia with dysregulated immunological status. Patients with pre-existing cardiovascular disease infected with COVID-19 have increased risk of severity and mortality. Literature available regarding the occurrence of bradycardia is limited, and electrophysiology studies in COVID-19 patients have shown sinus bradycardia, heart block, bundle branch block, and intraventricular conduction delay. The pathophysiological mechanism regarding the occurrence of bradycardia is not yet known entirely. Cardiac manifestations could be attributed to multiple clinical etiologies, including direct viral myocardial damage, inflammatory response, hypoxia, hypotension, downregulation of angiotensin-converting enzyme 2 (ACE-2), drug toxicity, and endogenous toxicity of catecholamine adrenergic status, also severe hypoxic damage of lungs by COVID-19 can also act as a trigger. We report one such case of bradycardia due to COVID-19 detected through intensive monitoring and managed successfully in the ICU of tertiary care dedicated COVID-19 hospital. Bradycardia in COVID-19 is a rare clinical phenomenon, could be a worst prognostic marker. If detected early may help in prognostication and, if managed appropriately, will avert a life-threatening complication.



O'Gallagher K, Shek A, Bean DM, Bendayan R, Papachristidis A, Teo JTH, et al. Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19. BMC Cardiovasc Disord. 2021;21(1):327.

Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14:247-50.

Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142(1):68-78.

Gopinathannair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020;59(2):329-36.

Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-38.

Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352-71.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8.

Ye F, Hatahet M, Youniss MA, Toklu HZ, Mazza JJ, Yale S. The Clinical Significance of Relative Bradycardia. WMJ. 2018;117(2):73-8.

Ye F, Winchester D, Stalvey C, Jansen M, Lee A, Khuddus M, Mazza J, Yale S. Proposed mechanisms of relative bradycardia. Med Hypotheses. 2018;119:63-7.

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-13.

Amir M, Yoseph H, Farisi ATA, Phie JKP, Adam ATS. Symptomatic Bradycardia in Covid-19 Hospitalized Patients: A Case Series. Int J Infect Dis. 2021;111:1-4.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.

Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003-8.

EA Amaratunga, DS Corwin, L Moran, R. Snyde. Bradycardia in Patients With COVID-19: A Calm Before the Storm. Cureus. 2020;2(6):6-13.

Lateef A, Fisher DA, Tambyah PA. Dengue and relative bradycardia. Emerg Infect Dis. 2007;13:650-1.

Mohamed MO, Gale CP, Kontopantelis E, Doran T, de Belder M, Asaria M, et al. Sex Differences in Mortality Rates and Underlying Conditions for COVID-19 Deaths in England and Wales. Mayo Clin Proc. 2020;95(10):2110-24.

Pathangey G, Fadadu PP, Hospodar AR, Abbas AE. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. Am J Physiol Lung Cell Mol Physiol. 2021;320(3):L301-30.




How to Cite

Kapoor, R., R., L., Devaraj, G. D., & Mohan, A. (2022). Hypoxic bradycardia: an enigma in coronavirus disease 2019. International Journal of Research in Medical Sciences, 10(12), 2956–2959. https://doi.org/10.18203/2320-6012.ijrms20223105



Case Reports